Objectives: EULAR and ACR are jointly supporting multi-phase development of SLE classification criteria based on weighted criteria and a continuous probability scale. Prior steps included item generation, item reduction, and hierarchical organization of candidate criteria using an evidence-based approach. Our objectives were to determine relative weights using multicriteria decision analysis (MCDA) and to set a preliminary threshold score for SLE classification.
INTRODUCTION
A multinational effort to develop new classification criteria for systemic lupus erythematosus (SLE) for clinical research, jointly supported by the European League Against Rheumatism (EULAR) and American College of Rheumatology (ACR), is underway. The overarching goal is to develop a system that identifies potential participants for clinical research studies, requiring a degree of homogeneity among subjects while simultaneously dealing with the extreme heterogeneity of SLE. [1] The aim was to design a system with the maximum combination of sensitivity and specificity for SLE, retaining face validity. While the classification criteria are not intended for diagnosis or clinical care, it is acknowledged that the only available "gold standard" for the presence of SLE is expert clinician opinion.
A 12 member Steering Committee was formed with input from EULAR and ACR leadership to oversee a four-phase process. [2] In Phase 1, items were collected through a Delphi exercise, [3] early SLE cohort, [4] and SLE patient survey. [5] During Phase 2, the list of potential criteria was narrowed using nominal group technique. [6, 7] Phase 3 began with a literature review for test performance characteristics of candidate criteria, and data-driven organization of criteria into domains. [1] This report outlines the latter part of Phase 3: criteria weighting and threshold score identification through a consensus-based multicriteria decision analysis (MCDA) approach. [8] [9] [10] The goal was to develop a criteria system producing a continuous measure of the relative probability that a case (i.e. particular combination of clinical features) could be characterized as SLE, and a threshold score above which a case could be definitely classified as SLE for clinical research.
METHODS
An international panel of SLE experts collected and rank-ordered patient case scenarios, participated in a 1.5-day in-person consensus meeting, and held post-meeting discussions by email and telephone.
SLE Expert Panel. The Steering Committee invited six additional experts
(three European, three North American) to form a 17 person SLE Expert Panel ("SLE experts") to assist with this phase and establish external validity of the criteria development process.
Development of patient case scenarios.
Each of the 17 SLE experts submitted 10 de-identified real cases based on patients from his/her own cohort in a standardized online form using REDCap (Research Electronic Data Capture), a secure, web-based application for research studies. [11] Each expert was asked to submit five cases with "definite" or "likely" SLE based on clinical judgment, and five cases in which they had considered but ultimately did not diagnose SLE and/or diagnosed a condition mimicking SLE such as rheumatoid arthritis, other inflammatory arthritis, Sjögren's syndrome, antiphospholipid antibody syndrome, or viral infection. [7] and subsequent work by the Steering Committee. [1] The REDCap form included 10 domains; each domain included 2-6 options (e.g. mucocutaneous domain: "none", "non-scarring alopecia", "oral ulcers", "subacute cutaneous lupus", "acute cutaneous lupus", "discoid lupus").
Rank
Experts were provided written instructions for scoring and a list of proposed definitions for each criterion. The instructions specified that within each domain, criteria were ordered from least to most supportive of SLE, and if multiple criteria were present in one domain only the single criterion furthest down the list (i.e. most supportive of SLE) should be scored. The instructions specified that a criterion should not be scored if a cause more likely than SLE existed (e.g. other autoimmune disease, malignancy, medication). Consensus decisions were entered into 1000minds TM software, which uses linear programming techniques to derive weights for each criterion. [12] c) Assessment of the face validity of the weights. Criteria weights were summed to produce an additive score for each case.
In
Only the highest-weighted criterion in each domain was counted toward the additive score, as specified in the written instructions (Table 1 ). The remainder of the 164 cases were scored and arranged in rank order from highest to lowest score. SLE experts reviewed a spreadsheet listing the criteria present in each of the 164 cases and anonymously voted whether they would classify each as SLE. For cases where expert opinion differed, RPN facilitated discussion to achieve full consensus about case classification. Cases were discussed in descending rank order (confidence that the case should be classified as SLE) until agreement on classifying as SLE could not be reached. was repeated once for those criteria whose calculated weights were inconsistent with expert opinion. Weights for all criteria were recalculated using 1000minds TM and additive scores were recalculated. SLE experts again anonymously voted on classifying each case as SLE, followed by a discussion facilitated by RPN to achieve consensus. The score of the last case for which expert consensus was achieved was the provisional full consensus upper threshold score.
Determining a lower threshold score. SLE experts attempted to set not only an upper threshold for definite SLE classification, but also a lower threshold for very low probability for classification. SLE experts discussed that individuals with scores falling between these two thresholds might be candidates for inclusion in observational studies or SLE prevention trials.
These patients could be considered as "potential" SLE (also labeled probable, possible or incomplete lupus, or undifferentiated connective tissue disease in the past). Due to insufficient time to perform this exercise at the November 2016 meeting, the lower threshold was addressed in a series of emails, secondary exercises, and conference calls in the next two months. SLE experts were asked to rate the cases that fell below the upper threshold score as "probable SLE", "possible SLE", or "unlikely SLE". The score of the case for which ≥70% indicated "unlikely SLE" was assigned as the lower threshold.
RESULTS
At the in-person meeting, SLE experts agreed that classification as SLE Review of the rank-ordering exercise. There was agreement on the cases that the majority of SLE experts ranked the highest and lowest, but a spectrum of ranking for cases in between (Figure 1) . This reflected the different relative weights that individual experts attached to particular criteria.  Renal domain. SLE experts decided that Class VI lupus nephritis was not specific for SLE based on clinical experience and lack of published data, and agreed upon removing Class VI nephritis. Importantly, since historical manifestations are included in the scoring system, previous evidence of class II, III, IV, or V lupus nephritis would be fully accounted for. These steps resulted in the updated definitions depicted in Table 1 . characterized by annular or papulosquamous (psoriasiform) cutaneous eruption observed by a clinician,* usually photodistributed. If skin biopsy is performed, typical changes must be present. [17] DLE is characterized by erythematousviolaceous cutaneous lesions with secondary changes of atrophic scarring, dyspigmentation, often follicular hyperkeratosis/plugging (scalp), observed by a clinician,* leading to scarring alopecia on the scalp. Lesions have a preference for the head and neck, especially the conchal bowl, but may be found in nearly any location. If skin biopsy is performed, typical changes must be present. [17]  Acute cutaneous lupus: Malar rash (localized) or maculopapular rash Revising criteria weights and provisional upper threshold score. The experts reviewed cases scored 60-70. Many of these cases had arthritis and most experts had voted to classify them as SLE. Therefore, the group felt that the weight assigned to arthritis was too low. After reviewing the specific criteria present in these cases, the mucocutaneous domain was re-organized based on expert consensus: acute cutaneous lupus was assigned the most influential position because it is most specific, and subacute cutaneous lupus and discoid lupus were grouped together and less influential than acute cutaneous lupus. Anonymous voting was repeated for pairwise comparisons including arthritis and mucocutaneous criteria. 1000minds TM software recalculated relative weights for all criteria and re-scored all cases using the revised weights.
MCDA to determine consensus weights using 1000minds
After this second round of MCDA, arthritis received a greater weight than prior, now identical to the weight of pleural or pericardial effusion. Acute cutaneous lupus was assigned the same weight as acute pericarditis and anti-dsDNA ( Table 2 ). The group repeated the anonymous voting exercise and reached consensus about the 82 highest-scored cases. Experts were unable to reach full consensus for the same case that determined the initial threshold. As that case now had a score of 83 using the revised criteria weights, a provisional consensus threshold was set as >83. Provisional criteria weights resulting from the MCDA exercise are shown in Table 2 . Lower threshold score. SLE experts individually rated the 82 cases below the upper threshold score as "probable SLE", "possible SLE", or "unlikely SLE" after the ACR 2016 meeting. The distribution of expert opinion is shown in Figure 2 . The score of the case for which ≥70% indicated "unlikely SLE" was 27. Only seven of 52 unique cases (13.5%) included in this exercise would be classified as "unlikely SLE" based on this lower threshold, and the remaining 86.5% would potentially be candidates for inclusion into observational or preventive studies. Through a series of telephone calls and emails, it became clear expert opinion varied considerably concerning the cases below the upper threshold. Additionally, the terms "probable", "possible" and "unlikely" were not being uniformly interpreted in this exercise and the duration of manifestations had not been specified. The SLE experts decided against assigning a lower threshold because it would exclude only a few cases from clinical studies. These efforts followed rigorous data-driven and expert-guided criteria development methodology in order to ensure high face and content validity of the items, and high discriminant validity of the criteria set. [19, 20] However, our literature review also revealed knowledge gaps about the sensitivity and specificity of some of the newly proposed criteria, thus expert consensus opinion was critical for decision making.
DISCUSSION
Consistent with developing other sets of classification criteria, [21, 22] there were significant discrepancies in ranking 20 cases regarding likelihood of SLE classification. Discussions centered on two aspects: 1) the quality and thus specificity of clinical and serological manifestations, and 2) attribution of manifestations to SLE versus other connective tissue diseases. Some experts expressed concern about misinterpretation of rosacea as acute cutaneous lupus, and about false positive anti-dsDNA via ELISA, each of which would reduce the specificity of the proposed classification system. To address these concerns, SLE experts agreed to include detailed definitions for each criterion to mitigate the risk of misinterpreting clinical signs and symptoms.
Because particular laboratory assays (e.g. Farr method for anti-dsDNA) are not uniformly available in all clinical settings, SLE experts decided that the testing method would not be specified, enabling SLE classification in a wide range of clinics.
The attribution of manifestations to SLE was discussed at length. For some of the cases, SLE experts were uncertain about how to interpret particular findings when SLE and another disease, such as primary antiphospholipid syndrome or Sjögren's syndrome, seemed equally likely. It became apparent that not all these decisions could be made with certainty, and that SLE experts from different centers could reach opposing conclusions.
The decision to exclude Class VI lupus nephritis was unanimous, given the lack of specificity of this end-stage finding. The discussions leading to the consensus elimination of mononeuropathy and cranial neuropathy were of greater interest. It was first mentioned that the specificities of these entities differed and that mononeuropathy is not specific for SLE. The group reached full consensus to eliminate mononeuropathy, and cranial neuropathy was initially retained. The group then discussed that cranial neuropathy is a very rare presenting sign in SLE [23] and that none of the 164 cases had cranial neuropathy. Experts reached a unanimous decision that the low prevalence of cranial neuropathy in SLE warranted eliminating it as a criterion.
Using a data-driven approach based on literature review [1] combined with an expert-driven MCDA process based on real patient cases, this third phase of the SLE classification project has led to precisely-defined criteria with individual weights derived through consensus decisions by 17 international SLE experts. The individual criteria weights have face validity, and taken together they depict current expert understanding of SLE. The preliminary classification criteria resulting from this third phase are being refined and validated in a large, distinct set of patient cases to finalize the project.
